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1. Introduction
Approximately 100 to 200 infants annually in the United States are infected with HIV (CDC,
2007). Most were born to mothers who were unaware of their infected HIV status or who
did not receive preventative services during their pregnancy to reduce transmission rates.
Therefore, in 2006, the CDC updated its guidelines for screening of various populations for
HIV, including pregnant women. Obstetricians and gynecologists are ideally suited to such
screening of their patients during annual exams and prenatal visits.
1.1. Screening for HIV infection during prenatal care
Screening only patients who reported risk factors for the HIV infection will miss many in‐
fected women. Therefore, the current recommendation is for implementation of universal
opt-out screening for HIV as early in pregnancy as possible (Branson et al., 2006). In this uni‐
versal opt-out screening method, a patient is informed that HIV testing will be performed as
a routine part of her prenatal care, unless she declines testing. She should be given written
or oral information about HIV, including an explanation of the infection, the meaning of
positive or negative test results, and measures that can be used to reduce perinatal transmis‐
sion. She should also be given the opportunity to ask further questions. However, no in‐
formed consent is required. If a patient declines screening, this should be documented in the
medical record, and screening should be offered at subsequent prenatal visits (Branson et
al., 2006; ACOG, 2008). Retesting is recommended with each new pregnancy. Although
these are the recommendations endorsed by the CDC and ACOG, healthcare providers must
be aware of the laws regarding screening in their own states, which may differ from the
above guidelines. Further information on state HIV testing laws can be obtained from state
and local health departments.
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Chou et al, estimated that the number needed to screen (NNS) in an area with 0.15% preva‐
lence would be between 3,500 to 12,170 to prevent 1 case of perinatally-acquired HIV infec‐
tion. In a high risk area with a prevalence of 5%, the NNS would be from 105 to 365 to
prevent 1 case of perinatally-acquired infection (Chou et, 2005).
At this time, both conventional and rapid screening tests for HIV are available to the health‐
care provider. Conventional testing consists of a screening test with an enzyme immunoas‐
say (ELISA), followed by confirmatory testing of a positive result with Western blot or
immunofluorescent antibody (IFA) testing. The sensitivity and specificity of this method of
testing is greater than 99%. False positive results are rare even in the setting with low preva‐
lence. Final results may not be available for several days to weeks. With rapid testing, a
blood or saliva test for HIV antibodies is performed, and the results are often available with‐
in an hour. Confirmatory testing of a preliminary positive result is still required before a di‐
agnosis of HIV can be made. A negative result with either the conventional or rapid
screening test indicates a woman does not have HIV, and no further testing is needed, un‐
less one suspects the patient was recently infected with HIV but has not produced an anti‐
body response to the virus (ACOG, 2008; Rahangdale & Cohan, 2008). If the initial screening
test is positive, but the confirmatory test is negative, the patient should be considered not
infected, and no further testing is necessary.
1.2. Rescreening in the third trimester
Studies from several countries have demonstrated that pregnant women seem to be at in‐
creased risk for acquisition of HIV over their non-pregnant counterparts (Moodley et al.,
2009; Gray et al., 2005; Sansom et al., 2003). Theories for this range from behavioral actions
of the woman or her partner that put her at increased risk, to physiologic changes associated
with pregnancy, including changes to the genital tract mucosa to changes in cellular immun‐
ity that may lead to increased susceptibility to HIV with pregnancy. Evidence has demon‐
strated that the rate of seroconversion during pregnancy may be as high as 2 to 3 percent in
some areas (Moodley et al., 2009; Gray et al., 2005; Sansom et al., 2003). A study by Sansom,
et al demonstrated that in a population with an HIV incidence of approximately 1 in 1000
person-years, the cost of repeat testing was offset by the savings in medical costs for preven‐
tion of an infected infant (Sansom et al., 2003). For the above reasons, repeat HIV testing is
recommended in certain populations in the third trimester, preferably before 36 weeks ges‐
tation (Branson et al., 2006; ACOG, 2008). These populations include:
• Women living in areas with a high incidence of HIV/AIDs, including the 20 states with
the highest incidence among women of child-bearing age
• Women who receive their healthcare in facilities where at least 1 in 1000 women screened
for HIV are found to be infected
• Women who engage in high-risk behavior that puts them at risk for HIV acquisition (in‐
jection drug use, exchange of sex for drugs or money, diagnosis of another sexually trans‐
mitted infection in the past year, a sex partner who engages in injection drug use or high-
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risk behaviors or is infected with HIV, or women who have had a new or more than one
sexual partner during their pregnancy)
• Women with signs or symptoms of acute HIV infection
1.3. Screening of women with undocumented HIV status
Studies indicate that between 40 and 85 percent of infants infected with HIV are born to
mothers whose HIV infection status is unknown prior to delivery (ACOG, 2008). If a woman
without documentation of HIV status presents to labor and delivery, opt-out rapid HIV test‐
ing should be performed at time of her initial presentation. A positive result should prompt
immediate treatment with antiretroviral prophylaxis without awaiting the result of confir‐
matory testing. If subsequent confirmatory testing shows the woman to be HIV negative,
treatment may be discontinued. Similarly, if a woman has an unknown HIV status in the
postpartum period, her infant should be tested by rapid screening. Antiretroviral treatment
should be initiated with a positive result, as the benefits of such treatment are maximized
when started within 48 hours of delivery (ACOG, 2008; Rahangdale & Cohan, 2008). Again,
treatment may be stopped if confirmatory testing is negative.
The  above  recommendation  for  prenatal  screening  for  HIV  infection  is  summarized  in
table  1.
Timing Screening test Confirmatory Test
Initial prenatal care visit Enzyme immunoassay (ELISA) Western blot or immunofluorescent
antibody (IFA) testing
Third trimester of pregnancy Repeat ELISA in women at high risk
for acquisition of HIV infection
Western blot or IFA testing
At time of labor and delivery for
women with undocumented HIV
status
Rapid HIV antibody screening test. Western blot or IFA testing
Table 1. CDC and ACOG recommendation for screening for HIV infection during pregnancy.
2. Evidences supporting the effectiveness of current interventions to
decrease mother-to-child transmission of HIV infection
Research in HIV infection reported several key factors in the transmission of the virus from
the mother to the infant. The risk factors for transmission can be divided into: virologic/
immunologic, maternal health status/behavior, and obstetrical factors (McGowan et al,
2000). High maternal plasma HIV-1 viral load, low maternal CD4 T-lymphocyte count, mul‐
tidrug-resistant HIV genotype will increase the transmission rate. Certain maternal behavior
(illicit drug use, cigarette smoking, breast feeding) or maternal health status (increased base‐
Screening for HIV Infection in Pregnancy
http://dx.doi.org/10.5772/54551
79
line weight or malnutrition or vitamin A deficiency) can increase the rate of mother-to-child
transmission. Some obstetrical factors (vaginal delivery, prolonged rupture of membrane,
fetal scalp electrode placement, chorioamnionitis, perineal lacerations, prematurity) can in‐
crease the vertical transmission rate (McGowan et al, 2000).
Other reports on perinatal transmission of HIV infection suggested that approximately 70%
of the infections transmitted to the infant during the labor and delivery process; only 30% of
the cases occurred during the antepartum period (Kourtis et al, 2006). Current interventions
to prevent perinatal transmission of HIV infection included: prophylaxis therapy with anti‐
retroviral medication, scheduled cesarean delivery and avoidance of breast feeding. These
interventions resulted in decreasing transmission rate to 2% (Cooper et al, 2002). We will ex‐
amine the evidence supporting these interventions.
2.1. Prophylaxis with antiretroviral agents
The Pediatric AIDS Clinical Trials Group (PACTG) 076 conducted a randomized controlled
study and in 1994 published its landmark results demonstrating a reduction in perinatal
HIV transmission by two-third with the antiretroviral medication Zidovudine (ZDV). HIV-
infected mothers in the study group received a three-part regimen of antiretroviral medica‐
tion. They received ZDV during pregnancy, intravenous ZDV during labor, and their infant
received ZDV orally for 6 weeks (Conner et al, 1994). This trial reported a decrease in trans‐
mission rate from 26% in the placebo group to 8% in those patients who received ZDV. Later
in the year of 1994, FDA approved the use of ZDV for reducing perinatal HIV transmission
and the U.S. Public Health Service Task Force (USPHSTF) and CDC published their recom‐
mendations for the administration of this regimen in an effort to reduce mother-to-child
transmission of the HIV infection (CDC, 2006).
In the late 1990s, additional antiretroviral medications were developed and the combined
use of three or more of these drugs was found to greatly inhibit viral replication and allow
improvement of the immune system. The combination of these medications was known as
highly active antiretroviral therapy (HAART). In 1998, USPHSTF and CDC issued recom‐
mendation regarding HAART: pregnant women should receive HAART if they required the
treatment for their disease status and all HIV-infected pregnant women should be offered
HAART. USPHSTF and CDC at that time acknowledged that the benefits and risks to the
fetus are uncertain (CDC, 1998). Four large U.S. and European cohort studies all concluded
that regimens with two or more antiretroviral drugs were more effective than the one-drug
regimen for reducing vertical transmission of the HIV infection (Cooper et al, 2002, Arch Pe‐
diatr Adolesc Med 2002, Clin Infect Dis 2005, Mandelbrot et al, 2001).
For women diagnosed late in pregnancy and were not able to receive a full course of antire‐
troviral treatment, a short course of antenatal treatment, although less effective, also was
proven to decrease perinatal transmission (Lallemant et al, 2000, Shaffer et al, 1999, Petra
study 2002, Wiktor et al, 1999, Dabis et al, 1999, Chou et al, 2005). There was some reduction
in the HIV infection transmission even when treatment was abbreviated to only antiretrovi‐
ral regimen during labor (Moodley et al, 2003, Taha et al, 2003, Guay et al, 1999). However,
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neonatal prophylaxis alone in a mother who did not receive antiretroviral prophylaxis thera‐
py was less effective in preventing HIV infection (Taha et al, 2003).
2.2. Scheduled cesarean delivery
A  meta-analysis  of  15  prospective  cohort  studies  by  the  International  Perinatal  HIV
Group  (The  International  Perinatal  HIV  Group,  1999)  included  8,533  mother-neonate
pairs.  Vertical  HIV transmission  was  reduced  by  50% when  the  mode  of  delivery  was
elective  cesarean  delivery.  The  effect  of  both  antiretroviral  therapy prophylaxis  and ce‐
sarean  delivery  further  reduced  HIV  transmission  by  87  percent  when  compared  with
other  modes  of  delivery  (either  vaginal  delivery  or  non-elective  cesarean  delivery)  and
no  antiretroviral  therapy.  However,  in  women  who  received  HAART  and  achieved
low  HIV  viral  load  levels  (defined  as  less  than  1,000  copies/  mL),  current  data  is  in‐
sufficient  to  determine  whether  elective  cesarean  delivery  would  offer  further  risk  re‐
duction.  ACOG  concluded  that  scheduled  cesarean  delivery  should  be  discussed  and
recommended  for  HIV-infected  women  whose  HIV-1  RNA  viral  load  exceeds  1,000
copies/mL.  Scheduled  cesarean  delivery  was  recommended as  early  as  38  weeks  gesta‐
tion to  reduce the risk of  labor or  of  prematurely ruptured membranes (ACOG, 1999).
2.3. Avoidance of breastfeeding
Breastfeeding was associated with an HIV transmission rate of 14% to 16% based on the re‐
sults of two meta-analyses of observational studies (Dunn et al, 1992, John et al, 2001). A re‐
view of the literature did not reveal any randomized, controlled trials evaluating the HIV
transmission rate associated with breastfeeding in the United States. A large, prospective co‐
hort study in Italy included 3,770 babies and concluded that HIV infection rates were signifi‐
cantly higher in babies who were breastfed after the authors adjusted for other factors,
including antiretroviral use (adjusted odds ratio, 10.20 [CI, 2.73 to 38.11]) (Arch Pediatr Ado‐
lesc Med., 2002, Chou et al, 2005).
In a study in Africa, women who breastfed and did not receive antiretroviral therapy had a
probability of transmitting the HIV infection of 36.7% (CI, 29.4% to 44.0%) at 24 months and
an infant mortality rate of 24.4% (CI, 18.2% to 30.7%). Those who formula fed their babies
had a transmission probability of 20.5% (CI, 14.0% to 27.0%) and an infant mortality rate of
20.0% (CI, 14.4% to 25.6%) (Nduati et al, 2000).
As a result, in many countries, including the United States where formula feeding is readily
available and inexpensive, breastfeeding is not recommended for infants of HIV-infected
women (WHO, 2000).
3. Potential harms/risks as the result of prenatal HIV screening
We will next explore the potential risks as the results of prenatal HIV screening and the po‐
tential harms of the recommended interventions to reduce perinatal transmission of HIV in‐
fection (Table 2).
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Maternal risks Fetal risks
Prenatal screening
Screened positive Discrimination from their partner
Social ostracization from family and
friends
Anxiety and depression
Abandonment and abuse from family
and friend
Screened falsely positive Anxiety
Social discrimination
Relationship problems
Unnecessary antiretroviral prophylaxis
during labor
Potential risk for elective termination
of pregnancy
Interventions to decrease perinatal
transmission
ART prophylaxis Hepatic toxicity and hypersensitivity
reaction (with Nevirapine)
Development of drug resistance
Gestational diabetes (with
combination therapy including
protease inhibitors)
Risks of neural tube defects with
Sustive (Efavirenz) with first trimester
exposure.
? Potential risk of mitochondrial
toxicity and disorder
Inconsistent data regarding increasing
risk for preterm birth and low-birth
weight
Scheduled cesarean delivery at 38
weeks
Post-operative morbidities, including:
postpartum fever, hemorrhage,
endometritis, urinary tract infection.
A trend toward higher risk of
respiratory distress syndrome among
neonates born by cesarean section
(when compared to those born via
vaginal delivery)
Table 2. Potential harms / risks from prenatal screening and strategic interventions to decrease perinatal transmission
of HIV infection:
According to Katz, prenatal screening for HIV in pregnancy aims to test a presumably
healthy population to discover asymptomatic women who are actually infected with HIV
infection. These pregnant women might not have or perceive that they have risk factors for
the HIV infection. This is different than the usual situation when a woman acknowledges
her risk for the infection and requests the screening test. Most women would agree to be
screened as they believe that they are doing everything they can for the health for their baby
but they might not realize the full implication of a positive HIV test result on their lives. In
some instances, they do not perceive that they are at risk for the infection and thus could be
quite unprepared to receive the positive diagnosis. This could result in adverse effect on
their emotional health, their pregnancy, and the family. Thus health care provider should
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always be well prepared to provide the appropriate emotional support for a possibility of
abnormal result (Katz, 2000).
Women tested positive for HIV infection can experience significant problems with discrimi‐
nation from their partner, social ostracization from their family and members of the com‐
munity (Provisional Committee on Pediatric AIDS, 1995, Samson et al, 1998). They were
found to have higher anxiety and depression scores and many women fear abandonment or
abuse, therefore, did not disclose their HIV status to their friend or families. (Lester, 1995)
although no increased risk for intimate partner violence was noted according to one cohort
study (Koenig et al, 2002, Chou et al, 2005)
Data on consequences of false-positive HIV infection diagnoses in pregnant women are
mainly anecdotal as reported by Sheon et al. The potential risks from false-positive results
included: elective termination of pregnancy, anxiety, social discrimination and relationship
problems with their partner (Sheon et al, 1994, Chou et al, 2005).
False positive results from rapid HIV testing during labor result in 4 women receiving un‐
necessary antiretroviral prophylaxis out of 4,849 women tested (Bulterys et al, 2004).
4. Risks of Antiretroviral Therapy (ART) to fetus
4.1. Potential teratogenic effects of ART
Efforts continue to increase our knowledge of the potential teratogenic effects of the antiretrovi‐
ral agents administered in pregnancy. The Antiretroviral Pregnancy Registry Steering Commit‐
tee published their recent report of antiretroviral exposures during pregnancy from January
1989 through July 2007. They did not identify an increased risk of birth defects in those exposed
to any of the antiretroviral therapy in the first trimester. The risk of birth defects among women
exposed to antiretroviral therapy in first trimester was 2.8 per 100 live births, which is not differ‐
ent from the risk of birth defects in women exposed to these agents in the second or third trimes‐
ter (2.6 per 100 live births), nor the CDC’s reported background rate of birth defects of 2.72 per
100 live births (www.APRegistry.com, 2007, Bardeguez, 2009).
Four retrospective reports associated Sustiva (Efavirenz) with neural tube defects in infants
born of mothers exposed to this medication in the first trimester (Bardeguez, 2009). There
are discrepant results with regard to mitochondrial toxicity and disorders in children ex‐
posed in utero to antiretroviral therapy. Two deaths believed to be due to mitochondrial dis‐
order were reported in children exposed in utero to nucleoside analogues (in specific, a
combination of Zidovudine and Lamivudine regimen) (Blanche et al, 1999). However, Euro‐
pean Collaborative report and systematic review of U.S. cohorts reports did not find evi‐
dence of clinical symptoms, or deaths due to mitochondrial dysfunction among HIV-
negative infants exposed to antiretroviral agents in utero (Bardeguez, 2009).
Of infants exposed in utero to Zidovudine who were followed at 4 years to 6 years of life. The re‐
ports were reassuring. Normal growth, cognitive, and developmental function were noted in
these infants at 4 years old. They did not sustain any tumors or deaths from cancer at 6 years old.
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4.2. Association between ART and preterm birth and low-birth weight
Inconsistent results were noted among the reports studying the effects of combination antire‐
troviral therapy on two obsterics outcomes: preterm birth and low birth-weight. Lorenzi et al in
1998 first reported the association between combination antiretroviral therapy with preterm
birth in a retrospective Swiss study of 30 women (Lorenzi et al, 1998). Subsequently, other Euro‐
pean studies reported a similar association between combination antiretroviral therapy and
preterm birth (The European Collaborative Study (ECS) andSwiss Mother + Child HIV Cohort
Study (Mo-CHiV), 2000, Grosch-Woerner et al, 2008). However, this association was not found
in U.S. studies until a recent study by Cotter et al. The authors prospectively collected the data
from 1990 through 2002 on 999 women receiving antiretroviral regimen during pregnancy.
They concluded that women who received combination therapy that included a protease inhib‐
itor had an increased risk of preterm delivery (Cotter et al, 2006).
In a largest analysis to date, Tuomola et al did not find an increased rate of premature birth
or low birth-weight infants among 2,123 HIV infected pregnant women from seven clinical
studies who received combination ART and gave birth from 1990 through 1998.
5. Risks of ART to mothers
A large prospective study evaluating the rates of maternal toxicity, pregnancy complica‐
tions, and peripartum morbidity among HIV-infected pregnant women receiving prenatal
care and ART concluded that adverse events were rare. Gestational diabetes was noted to be
highest among women who received combination therapy including protease inhibitors ei‐
ther before or during first trimester (Watts et al, 2004). Reports of potential risks of hepatic
toxicity and hypersensitivity reaction were noted in pregnant women receiving the drug Ne‐
virapine (Bardeguez, 2009).
Another valid concern is the potential development of drug resistance when ART was ad‐
ministered to the mother for a short period during pregnancy. Drug resistance was noted in
20 – 69% of women who received only intrapartum prophylaxis with single-dose nevira‐
pine. This could decrease the choice of medications for these women should they later need
treatment for their disease. Although, there are reports that this observed resistance dis‐
solved over time. (Bardeguez, 2009). Limited exposure to zidovudine alone did not alter ma‐
ternal disease progression, time until development of AIDS or death, or development of
genotypic zidovudine resistance (Bardeguez et al, 2003).
6. Potential maternal risks from scheduled cesarean delivery
Cesarean deliveries could result in significant complications when compared to vaginal de‐
livery even for HIV-negative women (Allen et al., 2003; Makoha et al., 2004). HIV-infected
women with an immunodeficient state could potentially at risk for post-operative infectious
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morbidities. Most studies report that HIV-infected women are at higher risk for post-opera‐
tive complications, mostly infectious, than the uninfected women (Coll et al., 2002; Grubert
el al., 1999; Vimercati et al., 2000). The rate of complications is higher in those with severe
immunodeficiency (Jamieson et al., 2007).
Read  et  al  conducted  a  largest  prospective  observational  study  which  included  1,186
HIV-infected  women  from  The  Women  and  Infants  Transmission  Study.  The  authors
evaluated  the  postpartum  morbidity  among  these  infected  women  according  to  their
mode of delivery. When compared to women who delivered vaginally, women who un‐
derwent scheduled cesarean delivery had an increased rate of postpartum fever (14.3%),
hemorrhage (7.1%),  endometritis  (5.4%),  urinary tract  infection (5.4%),  and any postpar‐
tum morbidity (26.7%) (Read et al, 2001).
7. Potential neonatal risks from scheduled cesarean delivery at 38 weeks
gestation
In  the  absence  of  medical  or  obstetrical  indications,  ACOG recommends  against  sched‐
uled  cesarean  delivery  at  less  than  39  weeks  of  gestation,  due  to  the  increased  risk  of
respiratory  morbidity  in  the  neonate  born  prior  to  this  gestational  age  (ACOG,  2001).
Neonatal  morbidity  is  high  even  among  those  neonates  born  via  cesarean  delivery  a
few  days  younger  than  39  weeks  (Tita  et  al,  2011).  However,  both  ACOG  and  U.S.
Public  Health  Service  recommend scheduled  cesarean  delivery  at  38  weeks  for  HIV-in‐
fected women with viral  load greater  than 1,000 copies/ml  (ACOG, 2001;  Public  Health
Service Task Force,  2010).  The scheduled cesarean delivery date is  set  at  one week ear‐
lier  than  the  usually  required  gestational  age  of  39  weeks  to  avoid  onset  of  spontane‐
ous  labor  and  rupture  of  membranes  which  could  increase  perinatal  transmission  of
HIV.  Livingston  et  al  and  the  IMPACT  Protocol  1025  Study  Group  evaluated  the  risk
of  neonatal  respiratory distress  syndrome according to the mode of  delivery and gesta‐
tional  age  at  delivery.  They  reported  that  the  mode  of  delivery  was  not  associated
with  respiratory  distress  syndrome.  However,  there  was  a  trend  toward  a  higher  risk
of  respiratory  distress  syndrome  among  neonates  delivered  by  either  elective  or  non-
elective  cesarean  section  when  compared  to  those  delivered  vaginally.  Two  out  of  227
neonates  born  via  scheduled  cesarean  delivery  at  38  weeks  gestation  had  respiratory
distress  syndrome (Livingston et  al.,  2010).
8. Conclusion
Current evidence supports prenatal HIV screening. The benefits from screening appear to
outweight the small risks / harms to the fetus and mothers from the treatment interventions
which significantly reduce perinatal-acquired HIV infection. We concluded the chapter by
discussing the obstacles to the HIV prenatal screening and prevention interventions. Prena‐
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tal screening for HIV infection and implementation of Protocol 076 were lauded as a major
public health success story and resulted in a significant decline in the number of children
infected with HIV from their mother. However, in the United States, there are still about
100–200 infants born every year with perinatally acquired HIV infection (CDC, 2007). Lack
of prenatal care remains one of the obstacles to prevention of perinatal transmission of HIV.
In the United States about 5 to 10% of women do not pursue prenatal care or receive insuffi‐
cient care (Kogan et al., 1998). HIV infected women, in particular, often do not receive pre‐
natal care. In New York City, 50% of women infected with HIV who delivered in at a
municipal hospital did not receive prenatal care (Minkoff et al., 1990). Of the HIV-infected
women surveyed in Philadelphia, only one third reported adequate prenatal care, and 20%
did not receive any care (Turner et al., 1996).
Even more worrisome, at the Medical Center of Louisiana in New Orleans, LA, 50% of the
HIV-infected parturients who did not have prenatal care but presented to the hospital for
labor and delivery did not disclose their HIV status to their physicians (CDC, 2004). Could it
be because the HIV-infected women did not know of the available interventions that they
put their infants at risk for the infection?
Several authors attempt to understand why HIV-infected women opted out of prenatal care
and available interventions to decrease vertical transmission. Rothpletz-Puglia et al solicited
opinions from a group of HIV-negative women about the process of prenatal HIV screening.
The authors reported that fear was a big factor for declining testing. The women are afraid
to find out they are HIV-infected. They are frightened to discover a partner’s infidelity. They
are fearful of being judged by their health care provider or of being denied medical care if
they tested positive (Rothpletz-Puglia et al, 2001).
Lancioni et al. reported that HIV-infected women did not participate in prenatal care be‐
cause they fear disclosing their status to their caretakers and being judged by them for con‐
tinuing the pregnancy (Lancioni et al., 1999). In a recent report by Lindau et al, HIV-infected
women who were interviewed were aware of the benefits of prophylaxis treatment yet most
received insufficient or no prenatal care. They knew of their HIV infection diagnosis but
most did not disclose their status to their caretaker when they presented for delivery at hos‐
pitals capable of providing prophylaxis treatment. They attributed health care providers’
lack of sensitivity, violations of confidentiality, disdain for HIV infection and substance
abuse as reasons for their non-participation in prenatal care, avoidance of treatment for HIV
infection, and non-disclosure of their HIV status. Denial and fear were other barriers to HIV
prophylaxis treatment (Lindau, 2006).
We agreed with Lindau et al that may be what is needed to further reduce perinatal trans‐
mission beyond the conventional models for prevention is to understand the HIV-infected
women’s point of view, their fears and concerns and to eliminate the disrespect treatment as
perceived by them from the health care providers. It is hope that we can create a medical
environment where these women will be confident of our compassion and care to disclose
their status and to want to seek prenatal care and HIV prophylaxis treatment (Lindau, 2006).
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Lastly,  not  only  obstetricians  and  gynecologists  need  to  follow  the  CDC  and  ACOG
guidelines  in  providing opt-out  prenatal  screening for  HIV they must  receive appropri‐
ate  training  for  pre  and  post  screening  counseling  and  must  ensure  patient  confiden‐
tiality.  More  importantly,  at  every  screening  they  must  be  prepared  for  positive
results:  they  must  be  compassionate  toward  those  tested  positive  and  must  have  re‐
sources  available  for  their  emotional  support  beyond  providing  the  standard  medical
interventions to  decrease vertical  transmission.
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